More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows

More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows
VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women with platinum-resistant ovarian cancer, with more than half of patients enrolled in a Phase 3 trial responding to a combination treatment. Since the OVAL trial (NCT03398655) has met pre-specified criteria, as an interim analysis found, an independent data safety monitoring committee (DSMC) is recommending that the study continue as planned. The results of the analysis showed that at least 10% more patients responded to VB-111 plus standard of care treatment than to standard therapy alone. The trial has recruited more than 100 of its targeted 400 participants. Enrollment is ongoing at 62 clinical sites across the United States and Israel, and is expected to expand to Europe and Japan later this year. For more information about study locations, go here. The findings from this pre-planned interim analysis were recently presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually due to the COVID-19 pandemic.  The poster was titled “Pivotal Study of VB-111 Combined with Paclitaxel vs. Paclitaxel for Treatment of Platinum-Resistant Ovaria
Subscribe or to access all post and page content.